HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: The Limited, Inc. spin-off

This article was originally published in The Rose Sheet

Executive Summary

The Limited, Inc. spin-off: Intimate Brands goes public with an offering of 40 mil. shares at $17 per share. In the first day of trading, Oct. 24, the issue closed at 17-5/8 and finished the week at 17-1/8. Nearly all of the proceeds will go to The Limited: about $250 mil. to "repay borrowings...which were used to fund a dividend to The Limited;" and up to $400 mil. will be used to pay off "certain intercompany obligations...to the Limited," the prospectus states. The Limited retains an 84% stake in the spin-off which includes the firm's Bath & Body Works and Victoria's Secret businesses, according to an updated registration statement filed Sept. 14. Originally, the spin-off was to have been called Intibrands...

You may also be interested in...



Intimate Brands Buyback Aiming For Un-Limited Growth Opportunities

The Limited is buying back the outstanding 16% of its Intimate Brands subsidiary in an effort to capitalize on growth opportunities between the two companies, Exec VP and Chief Financial Operator V. Ann Hailey said during a 1Feb. 4 conference call

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel